The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma

著录项

• 来源
  《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共1页
• 作者

  Diallo B.; Massonnet G.; El-Botty R.; Raymondie C.; Howes C.; Wilson J.; Smith A.; Roman-Roman S.; Smith P.; Davies E.; Decaudin D.; Nemati F.;

  展开▼
• 作者单位

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词

• 入库时间 2022-08-18 10:57:41